Multiple sclerosis : clinical and laboratory research
-
Observational Study
Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
The effects of disease-modifying therapies (DMTs) on region-specific brain atrophy in multiple sclerosis (MS) are unclear. ⋯ DMT-H treatment may be associated with slower rates of subcortical GM atrophy, especially of the thalamus and putamen. Thalamic and putaminal volumes are promising imaging biomarkers in MS.